Daiichi Sankyo Co Ltd
TSE:4568
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
3 825
6 148
|
Price Target |
|
We'll email you a reminder when the closing price reaches JPY.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one Daiichi Sankyo Co Ltd stock under the Base Case scenario is 5 494.59 JPY. Compared to the current market price of 4 435 JPY, Daiichi Sankyo Co Ltd is Undervalued by 19%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Daiichi Sankyo Co Ltd
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for Daiichi Sankyo Co Ltd cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Daiichi Sankyo Co., Ltd., a prominent player in the global pharmaceuticals sector, has cemented its position as a leader through innovation and strategic expansion. Founded in 2005 from the merger of Daiichi Pharmaceutical and Sankyo Company, the company has continually focused on research and development, particularly in the fields of oncology, cardiovascular medicine, and vaccines. This dedication has resulted in a robust pipeline of transformative therapies, including the highly anticipated antibody-drug conjugates that address unmet medical needs. Investors are drawn to Daiichi Sankyo not just for its impressive portfolio but also for its commitment to quality and sustainability, underpi...
Daiichi Sankyo Co., Ltd., a prominent player in the global pharmaceuticals sector, has cemented its position as a leader through innovation and strategic expansion. Founded in 2005 from the merger of Daiichi Pharmaceutical and Sankyo Company, the company has continually focused on research and development, particularly in the fields of oncology, cardiovascular medicine, and vaccines. This dedication has resulted in a robust pipeline of transformative therapies, including the highly anticipated antibody-drug conjugates that address unmet medical needs. Investors are drawn to Daiichi Sankyo not just for its impressive portfolio but also for its commitment to quality and sustainability, underpinned by a strong financial foundation that supports ongoing growth.
As the global healthcare landscape evolves, Daiichi Sankyo is well-prepared to adapt and capitalize on emerging opportunities, such as the accelerating demand for personalized medicine and innovative treatment modalities. The company's strategic partnerships and collaborations, particularly with international giants, have further bolstered its reach and resource capacity, making it a formidable force in the industry. For investors, this dynamic blend of innovative prowess, strategic foresight, and sound financial management makes Daiichi Sankyo an attractive option, promising potential long-term growth as it continues to push the boundaries of what's possible in healthcare.
Daiichi Sankyo Co., Ltd. is a Japanese pharmaceutical company that operates primarily in the healthcare sector. It focuses on innovative research and development, mainly in the following core business segments:
-
Pharmaceuticals: This is the largest segment, encompassing the research, development, manufacturing, and marketing of prescription pharmaceutical products. Daiichi Sankyo has a strong emphasis on cardiovascular, oncology, and vaccine development. The company aims to deliver innovative drugs and therapies through significant R&D investment.
-
Biosimilars: As the biopharmaceutical industry grows, Daiichi Sankyo has also entered the biosimilars market. This segment involves the development and commercialization of biologically similar products that match the efficacy and safety profiles of existing biologics, providing more affordable options.
-
Consumer Healthcare: This segment includes over-the-counter (OTC) products, health supplements, and other consumer-oriented health solutions. Though smaller compared to the pharmaceuticals segment, it allows Daiichi Sankyo to diversify its revenue streams and reach a broader audience.
-
Regenerative Medicine: Daiichi Sankyo is also investing in regenerative medicine, focusing on therapies that aim to repair or replace damaged tissues and organs. This reflects their strategy to innovate and stay ahead in emerging therapeutic areas.
-
Global Markets: The company has a strong presence not only in Japan but also in international markets, particularly in Europe and North America. This global reach allows it to tap into diverse markets and increase its overall sales and market share.
Overall, Daiichi Sankyo's core business segments are designed to leverage its strong R&D capabilities while addressing global health needs through innovative products and therapies.
Daiichi Sankyo Co., Ltd. possesses several unique competitive advantages that set it apart from its rivals in the pharmaceutical industry:
-
Strong Research and Development (R&D) Capabilities: Daiichi Sankyo is known for its robust investment in R&D, which enables the company to innovate and develop new drugs. Their focus on both small molecule pharmaceuticals and biopharmaceuticals allows for a diverse pipeline of therapeutic options.
-
Focused Therapeutic Areas: The company has prioritized specific therapeutic areas, such as oncology, cardiovascular, and immunology. This strategic focus allows Daiichi Sankyo to hone expertise and resources within these domains, potentially leading to more effective treatments and stronger market positions.
-
Strategic Partnerships and Collaborations: Daiichi Sankyo frequently engages in collaborations with other pharmaceutical companies and research institutions. These partnerships provide access to additional resources, expertise, and technologies, enhancing their product development capabilities.
-
Robust Pipeline of Products: The company has a strong pipeline of drugs in various stages of development, including blockbuster medications. Their commitment to developing both novel therapeutic candidates and improving existing treatments positions them well for market success.
-
Global Presence and Market Access: With operations in multiple countries and a broad network, Daiichi Sankyo has established significant market access. Their global footprint enables them to navigate diverse healthcare ecosystems and adapt to regional market needs.
-
Strong Financial Position: A solid balance sheet and cash flow allow Daiichi Sankyo to invest heavily in R&D and marketing while managing operational risks effectively. This financial strength can provide a buffer during economic downturns and may allow for opportunistic acquisitions.
-
Commitment to Quality and Compliance: The commitment to high standards of quality and regulatory compliance builds trust with healthcare professionals and patients. This reputation enhances brand loyalty and can be a deciding factor for healthcare providers when choosing products.
-
Innovation in Delivery Systems: Daiichi Sankyo has focused on developing innovative drug delivery systems that improve patient adherence and therapeutic outcomes, distinguishing their products from competitors.
-
Strong Intellectual Property (IP) Portfolio: Protecting their innovations through patents provides a competitive edge, preventing rivals from duplicating their breakthroughs and maintaining exclusivity for a certain period.
By leveraging these competitive advantages, Daiichi Sankyo Co., Ltd. is well-positioned to compete effectively in the dynamic pharmaceutical landscape.
Daiichi Sankyo Co., Ltd., like many pharmaceutical companies, faces a range of risks and challenges in the near future. Here are some of the key ones:
-
Regulatory Risks: The pharmaceutical industry is heavily regulated. Changes in regulations or delays in approval processes can affect the launch of new drugs and impact the timeline for realizing revenues from these products.
-
Product Pipeline Dependency: The success of Daiichi Sankyo is heavily reliant on its product pipeline. If new drugs fail in clinical trials or do not receive regulatory approval, it can significantly impact revenue forecasts and market confidence.
-
Market Competition: The pharmaceutical market is highly competitive, with numerous players vying for market share. Daiichi Sankyo faces competition from both established pharmaceutical giants and emerging biotechs. This can lead to price pressures and reduced profitability.
-
Patent Expiration and Generic Competition: As patents on key drugs expire, Daiichi Sankyo may face increased competition from generic versions, which could erode market share and revenue.
-
Market Access and Pricing Pressure: There’s increasing scrutiny on drug pricing from governments and healthcare providers globally. This could lead to challenges in obtaining favorable pricing and reimbursement for its products, affecting revenue.
-
Global Economic Factors: Economic downturns or fluctuations can impact healthcare spending and patient access to therapies. Additionally, exchange rate volatility can affect revenue, particularly given Daiichi Sankyo's global operations.
-
Supply Chain Disruptions: Disruption in the supply chain, whether due to geopolitical issues, pandemics, or natural disasters, can hinder production and the timely delivery of products to market.
-
Technological Advances and Shifts: Rapid advancements in biotechnology and changing methodologies in drug development could shift the competitive landscape. Daiichi Sankyo must adapt and possibly pivot its strategy to stay relevant.
-
Talent Retention and Acquisition: The pharmaceutical industry relies heavily on skilled professionals in research, regulatory affairs, and sales. Attracting and retaining top talent is crucial for innovation and commercial success.
-
Public Perception and Legal Risks: Any adverse events related to its products can lead to litigation and damage to the company's reputation. Public perception of pharmaceutical companies is also increasingly scrutinized, and any negative headlines can have lasting impacts.
To navigate these challenges successfully, Daiichi Sankyo will need to continue innovation, engage in effective risk management, and maintain strong relationships with regulatory bodies and stakeholders.
Revenue & Expenses Breakdown
Daiichi Sankyo Co Ltd
Balance Sheet Decomposition
Daiichi Sankyo Co Ltd
Current Assets | 1.9T |
Cash & Short-Term Investments | 848.5B |
Receivables | 531.8B |
Other Current Assets | 515.9B |
Non-Current Assets | 1.4T |
Long-Term Investments | 154.5B |
PP&E | 458.4B |
Intangibles | 311.4B |
Other Non-Current Assets | 476.6B |
Current Liabilities | 643.9B |
Accounts Payable | 502.8B |
Other Current Liabilities | 141.1B |
Non-Current Liabilities | 1T |
Long-Term Debt | 101.1B |
Other Non-Current Liabilities | 929.3B |
Earnings Waterfall
Daiichi Sankyo Co Ltd
Revenue
|
1.8T
JPY
|
Cost of Revenue
|
-420B
JPY
|
Gross Profit
|
1.3T
JPY
|
Operating Expenses
|
-1T
JPY
|
Operating Income
|
303.4B
JPY
|
Other Expenses
|
-53B
JPY
|
Net Income
|
250.4B
JPY
|
Free Cash Flow Analysis
Daiichi Sankyo Co Ltd
JPY | |
Free Cash Flow | JPY |
Daiichi Sankyo's fiscal Q2 saw revenue rise by 21.5% year-on-year to JPY 882.7 billion, largely driven by strong performances in oncology, specifically from products like Enhertu. Core operating profit surged by 74.8% to JPY 166.6 billion. Notably, the company raised its full-year revenue guidance by JPY 80 billion to JPY 1.83 trillion. This upward revision is influenced by expected sales increases for Lixiana and Enhertu, alongside favorable foreign exchange impacts. The adjusted core operating income forecast also improved by JPY 50 billion to JPY 260 billion, reflecting solid growth momentum.
What is Earnings Call?
Profitability Score
Profitability Due Diligence
Daiichi Sankyo Co Ltd's profitability score is 60/100. The higher the profitability score, the more profitable the company is.
Score
Daiichi Sankyo Co Ltd's profitability score is 60/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Daiichi Sankyo Co Ltd's solvency score is 91/100. The higher the solvency score, the more solvent the company is.
Score
Daiichi Sankyo Co Ltd's solvency score is 91/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Daiichi Sankyo Co Ltd
According to Wall Street analysts, the average 1-year price target for Daiichi Sankyo Co Ltd is 6 562 JPY with a low forecast of 5 656 JPY and a high forecast of 7 980 JPY.
Dividends
Current shareholder yield for Daiichi Sankyo Co Ltd is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Daiichi Sankyo Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 16,033 full-time employees. The company went IPO on 2005-09-28. The firm is involved in the research, development, manufacture and sale of pharmaceuticals, as well as the provision of intermediates and basic materials for pharmaceutical producing in Japan, the United States, Europe and other markets. The firm is also engaged in the research, development, manufacture and sale of over-the-counter drugs and vaccines, the provision of administrative services such as human resources and accounting services, real estate leasing and insurance agency business.
Contact
IPO
Employees
Officers
The intrinsic value of one Daiichi Sankyo Co Ltd stock under the Base Case scenario is 5 494.59 JPY.
Compared to the current market price of 4 435 JPY, Daiichi Sankyo Co Ltd is Undervalued by 19%.